An observational study examining the effect of comorbidity on the rates of persistence and adherence to newly initiated oral anti-hyperglycaemic agents

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 12, 2013, Pages 1336-1344

  O'Shea, Miriam P ^a   Teeling, Mary ^a   Bennett, Kathleen ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Adherence; Comorbidity; Oral anti hyperglycaemic therapy; Persistence; Pharmacoepidemiology; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; THIAZOLIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL;

ADHERENCE; COMORBIDITY; ORAL ANTI-HYPERGLYCAEMIC THERAPY; PERSISTENCE; PHARMACOEPIDEMIOLOGY; TYPE 2 DIABETES;

ADMINISTRATION, ORAL; ADULT; AGED; COHORT STUDIES; COMORBIDITY; DATABASES, FACTUAL; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; IRELAND; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 84888440090     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3535     Document Type: Article

References (50)

1. Brown MT, Bussell JK. Medication adherence: who cares? Mayo Clin Proc 2011; 86(4): 304-314.
2. Greevy RA, Huizinga MM, Roumie CL, et al. Comparison of persistence and durability among three oral antidiabetic therapies using electronic prescription - fill data: the impact of adherence requirements and stockpiling. Clin Pharmacol Ther 2011; 90(6): 813 - 819.
3. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract 2011; 65(3): 314-322.
4. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11(1): 44-47.
5. DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes a meta-analysis. Med Care 2002; 40:794-811.
6. Reginster JY. Adherence and persistence: impact on outcomes and health care resources. Bone 2006; 38(2 suppl 2): S18-S21.
7. Hill MN. Houston Miller N, DeGeest S. On behalf of the American society of hypertension writing group. Adherence and persistence with taking medication to control high blood pressure. J Am Soc Hypertens 2011; 5(1): 56-63.
8. Salas M, Hughes D, Zuluaga A, et al. Cost of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health 2009; 12(6): 915-922.
9. Odegard PS, Capoccia K. Medication taking and diabetes a systematic review of the literature. Diabetes Educ 2007; 33(6): 1014-1029.
10. Rozenfeld Y, Hunt JS, Plauschinat C, et al. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 2008; 14(2): 71-75.
11. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effects of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166(17): 1836-1841.
12. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004; 27(5): 1218-1224.
13. Gregoire JP, Sirois C, Blanc G, et al. Persistence patterns with oral antidiabetes drug treatment in newly treated patients - a population-based study. Value Health 2010; 13(6): 820-828.
14. Odegard PS, Gray SL. Barriers to medication adherence in poorly controlled diabetes mellitus. Diab Educ 2008; 34(4): 692-697.
15. Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer sponsored health insurance. Clin Thera 2005; 27(7): 1064-1073.
16. Druss B, Marcus SC, Olfson M, et al. Comparing the national economic burden of five chronic conditions. Health Aff 2001; 20(6): 233-241.
17. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002; 162: 2269-2276.
18. Yang Y, Thumula V, Pace PF, et al. Predictors of medication non adherence among patients with diabetes in Medicare part D programs: a retrospective cohort study. Clin Thera 2009; 31(10): 2178-2188.
19. Balkrishnan R, Rajagopalan R, Camcho FT, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Thera 2003; 25(11): 2958-2971.
20. Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care 2006; 29(3): 725-731.
21. Woodard LD, Urech T, Landrum CR, et al. The impact of comorbidity type on measures of quality for diabetes care. Med Care 2011; 49(6): 605-610.
22. Toussi M, Choleau C, Reach G, et al. A novel method for measuring patients' adherence to insulin dosing guidelines: introducing indicators of adherence. BMC Med Inform Decis Mak 2008; 8:55.
23. Osterberg L, Blaschke T. Adherence to medication. New Engl J Med 2005; 353: 487-497.
24. Kogut SJ, Andrade SE, Willey C, Larrat EP. Non adherence as a predictor of antidiabetic drug therapy intensification. Pharmacoepidemiol Drug Saf 2004; 13: 591-598.
25. Fishman PA, Goodman MJ, Hornbook MC, et al. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care 2003; 41(1): 84-99.
26. Sloan KL, Sales AE, Liu CF et al. Construction and charcteristics of the RxRisk-V: A VA adapted pharmacy based case -mix instrument. Med Care 2003; 41(6): 761-774.
27. O'Shea M, Teeling M, Bennett K. The prevalence and ingredient cost of chronic comorbidity in the Irish elderly population with treated type 2 diabetes: a retrospective cross-sectional study using a national pharmacy claims database. BMC Health Serv Res 2013; 13: 23.
28. Shalansky SJ, Levy AR. Effect of number of medications on cardiovascular therapy adherence. Ann Pharmacother 2002; 36: 1532-1539.
29. Cheong C, Barner JC, Lawson KA, et al. Patient adherence and reimbursement amount for antidiabetic fixed dose combination products compared with duel therapy among Texas Medicaid recipients. Clin Thera 2008; 30(10): 1893-1907.
30. Horne R, Weinman J. Patient beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999; 47(6): 555-567.
31. Donnan PT, MacDonald TM, Morrist AD. For the DARTS/MEMO collaboration. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes a retrospective cohort study. Diabet Med 2002; 19: 279-284.
32. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid lowering therapy. Arch Inten Med 2005; 165(10): 1147-1152.
33. Monane M, Bohn RL, Gurwitz JH, et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance. Results from a population-based study of the elderly. Am J Hypertens 1997; 10: 697-704.
34. Siegel D, Lopez J, Meier J. Antihypertensive medication adherence in the Department of Veteran Affairs. Am J Med 2007; 120: 26-32.
35. Morris AB, Li J, Kroenke K, et al. Factors associated with drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy 2006; 26(4): 483-492.
36. Wang PS, Avorn J, Brookhart MA, et al. Effects of noncardiovascular comorbidities on anti-hypertensive use in elderly hypertensives. Hypertension 2005; 46: 273-279.
37. Kerr EA, Heisler M, Krein SL, et al. Beyond comorbidity counts: how do comorbidity type and severity influence diabetes patients' treatment priorities and self-management? J Gen Intern Med 2007; 22(12): 1600-1640.
38. Beverly EA, Wray LA, Chiu CJ, et al. Perceived challenges and priorities in co-morbidity management of older patients with type 2 diabetes. Diabet Med 2011; 28(7): 781-784.
39. Vitry AI, Roughead EE, Preiss AK, et al. Influence of comorbidities on therapeutic progression of diabetes treatment in Australian veterans: a cohort study. PLoS one 2010; 5(11): e14024.
40. Kalsekar ID, Madhavan SS, Amonkar MA, et al. Depression in patients with type 2 diabetes: impact on adherence to oral hypoglycaemic agents. Ann Pharmacother 2006; 40: 605-611.
41. Katon W, Russo J, Lin EHB, et al. Diabetes and poor disease control: is comorbid depression associated with medication adherence or lack of treatment intensification. Psychosom Med 2009; 71(9): 965-972.
42. Caughey GE, Preiss AK, Vitry AI, et al. Does antidepressant medication use affect persistence with diabetes medicines? Pharmacoepidemiol Drug Saf 2013; 22: 615-622.
43. Denzii CM, Kawabata H, Tran M. Effects of once-daily and twice daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002; 95(1): 68-71.
44. Jermendy G, Wittmann I, Nagy L, et al. Persistence of oral antidiabetic treatment in patients with type 2 diabetes mellitus. Med Sci Monit 2012; 18(2): 72-77.
45. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15: 565-574.
46. Hess LM, Raebel MA, Conner DA, et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006; 40: 1280-1288.
47. Zaharan NL. Pharmacoepidemiology of diabetes mellitus in a national population. PhD thesis. Trinity College Dublin; 2010.
48. Usher C, Creed L, Bennett K, et al. Prescribing for patients with diabetes in the community drug schemes. Ir Med J 2006; 99(6): 181-183.
49. World Health Organisation. Adherence to long term therapies: evidence for action. Geneva, World Health Organisation ISBN 92 4 154599 2, 2003.
50. Hayes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; 16(2): CD000011.